valine has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Worth, LJ | 1 |
2 other study(ies) available for valine and bortezomib
| Article | Year |
|---|---|
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2012 |
Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies.
Topics: Acyclovir; Aged; Antineoplastic Agents; Antiviral Agents; Bortezomib; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Outcome Assessment, Health Care; Time Factors; Transplantation, Autologous; Valacyclovir; Valine; Varicella Zoster Virus Infection | 2016 |